Syndax axatilimab misses primary endpoint in Phase 2 IPF trial, drops further development in indication
Syndax reported topline results from its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis. The study missed its primary goal, leading Syndax to drop further development of axatilimab in idiopathic pulmonary fibrosis. Safety looked comparable to placebo, with no new safety signals flagged. Ongoing ax